文献速递前列腺癌

低PSA高分级前列腺癌的临床与基因组特征

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-02-22

结果显示,Gleason 8-10患者中PSA与前列腺癌特异性死亡率呈U型关系,PSA≤2.5ng/ml者死亡风险显著升高,且与神经内分泌/小细胞标志物高表达相关,提示可能对雄激素剥夺治疗反应不佳。

要点

  • Gleason 8-10患者中PSA与PCSM呈U型关系,PSA≤2.5ng/ml者风险最高
  • 低PSA高分级肿瘤神经内分泌/小细胞标志物表达更高
  • 低PSA高分级患者接受放疗时ADT生存获益不显著

核心结论

  • 低PSA高分级前列腺癌的前列腺癌特异性死亡风险很高,可能对雄激素剥夺治疗反应不佳,并与神经内分泌基因组特征相关。

主要发现

  • Gleason 8-10且PSA≤2.5ng/ml者的PCSM显著高于PSA>2.5ng/ml的标准高危/极高危患者(AHR 2.15,p=0.002;47个月PCSM 14% vs 4.9%)。
  • 接受放疗的Gleason 8-10患者中,ADT与PSA>2.5ng/ml者的生存获益相关(AHR 0.87;p<0.001),但与PSA≤2.5ng/ml者无关(AHR 1.36;p=0.084;交互作用p=0.021)。
  • Gleason 8-10肿瘤中,PSA≤2.5ng/ml与神经内分泌/小细胞标志物表达更高相关(p=0.046),Gleason≤7疾病中无此关系。

关键数值与推荐

  • Gleason 8-10且PSA≤2.5ng/ml者47个月PCSM为14%,而PSA>2.5ng/ml的标准高危/极高危者为4.9%。
  • Gleason 8-10患者放疗时,ADT与PSA>2.5ng/ml者生存获益相关(AHR 0.87;p<0.001),PSA≤2.5ng/ml者无显著获益(AHR 1.36;p=0.084)。

临床怎么用

  • 对Gleason 8-10且PSA≤2.5ng/ml的前列腺癌患者应识别为极高危人群,现有列线图和治疗范式可能需要修正。
  • 该类患者接受放疗时不应默认ADT获益,需个体化评估,并关注神经内分泌分化可能。

局限性

  • 本研究为回顾性研究,数据来自数据库,可能存在选择偏倚和未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The consequences of low prostate-specific antigen (PSA) in high-grade (Gleason 8-10) prostate cancer are unknown. OBJECTIVE: To evaluate the clinical implications and genomic features of low-PSA, high-grade disease. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective study of clinical data for 494 793 patients from the National Cancer Data Base and 136 113 patients from the Surveillance, Epidemiology, and End Results program with cT1-4N0M0 prostate cancer (median follow-up 48.9 and 25.0 mo, respectively), and genomic data for 4960 patients from the Decipher Genomic Resource Information Database. Data were collected for 2004-2017. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Fine-Gray and Cox regressions were used to analyze prostate cancer-specific mortality (PCSM) and all-cause mortality, respectively. RESULTS AND LIMITATIONS: For Gleason 8-10 disease, using PSA 4.1-10.0ng/ml (n=38 719) as referent, the distribution of PCSM by PSA was U-shaped, with an adjusted hazard ratio (AHR) of 2.70 for PSA ≤2.5ng/ml (n=3862, p<0.001) versus 1.97, 1.36, and 2.56 for PSA of 2.6-4.0 (n=4199), 10.1-20.0 (n=17 372), and >20.0ng/ml (n=16 114), respectively. By contrast, the distribution of PCSM by PSA was linear for Gleason ≤7 (using PSA 4.1-10.0ng/ml as the referent, n=359 898), with an AHR of 0.41 (p=0.13) for PSA ≤2.5ng/ml (n=37 812) versus 1.38, 2.28, and 4.61 for PSA of 2.6-4.0 (n=54 152), 10.1-20.0 (n=63 319), and >20.0ng/ml (n=35 459), respectively (pinteraction<0.001). Gleason 8-10, PSA ≤2.5ng/ml disease had a significantly higher PCSM than standard high-risk/very high-risk disease with PSA >2.5ng/ml (AHR 2.15, p=0.002; 47-mo PCSM 14% vs 4.9%). Among Gleason 8-10 patients treated with radiotherapy, androgen deprivation therapy was associated with a survival benefit for PSA >2.5ng/ml (AHR 0.87; p<0.001) but not ≤2.5ng/ml (AHR 1.36; p=0.084; pinteraction=0.021). For Gleason 8-10 tumors, PSA ≤2.5ng/ml was associated with higher expression of neuroendocrine/small-cell markers compared to >2.5ng/ml (p=0.046), with no such relationship for Gleason ≤7 disease. CONCLUSIONS: Low-PSA, high-grade prostate cancer has very high risk for PCSM, potentially responds poorly to androgen deprivation therapy, and is associated with neuroendocrine genomic features. PATIENT SUMMARY: In this study, we found that low-prostate-specific antigen, high-grade prostate cancer has a very high risk for prostate cancer death, may not respond well to androgen deprivation therapy, and is associated with neuroendocrine genomic features. These findings suggest that current nomograms and treatment paradigms may need modification.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mahal BA, Yang DD, Wang NQ, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018. PMID: 29478736. doi:10.1016/j.eururo.2018.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。